Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of ...

Roche has pledged to build a giant weight-loss drug factory in the US. The plans form part of a $50bn (£37bn) pledge aimed at ...

Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

The filing also showed UnitedHealth CEO Andrew Witty's total compensation for 2024 was $26.3 million, compared with $23.5 ...

(Reuters) -Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract ...

With a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.